Short answer
Spero Therapeutics Inc (SPRO) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$44M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$44M
- −499.8% YoY · −363.5% QoQ
- EPS (diluted)
- −$0.77
- −492.3% YoY · −381.3% QoQ
Source: XBRL data from the Spero Therapeutics Inc (SPRO) Q3 2026 10-Q on SEC EDGAR. USD.
Spero Therapeutics Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0 vs $5.442M YoY, reflecting no grant or collaboration revenue
- Net loss $44.278M vs $7.382M YoY, operating loss $41.913M vs $7.916M
- Worst-performing line: grant revenue $0 vs $2.394M, collaboration revenue $0 vs $3.048M
- Cash $107.9M; operating cash use $32.098M, financing provided $99.761M from milestone and royalty financing
- SP001 Phase 2 IgG4-RD trial expected Q2 2027, subject to FDA IND clearance; funding projected into second half of 2029
Risk Factors
- New lead-candidate dependence: July 8, 2026 Innovent Agreement shifted focus to SP001, now the only clinical-stage candidate
- Most material update: Utebzi FDA approval and SPR206/SPR720 termination increased reliance on SP001 development and GSK commercialization
- Regulatory risk: May 2026 House draft report could bar FDA consideration of China-generated clinical data supporting SP001’s IND
- Competitive risk: SP001 faces approved UPLIZNA and multiple IgG4-related disease candidates in development
- Liquidity risk: $105.0 million HCRx Notes limit retained GSK proceeds to 35% after repayment terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spero Therapeutics Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.